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710Therapeutic lifestyle changes,
including exercise, are the ﬁrst
line of treatment for patients
with metabolic syndrome. The
health beneﬁts of exercise have
been widely described, the most
notable of which is an increase in
cardiorespiratory ﬁtness. Impor-tantly, cardiorespiratory ﬁtness has been identiﬁed as the
strongest independent predictor of both all-cause and
cardiovascular disease mortality in nearly every population in
which it has been examined (5–7).
Statins, a class of hydroxymethylglutaryl-coenzyme A reduc-
tase inhibitors that lower low-density lipoprotein cholesterol
(LDL-C), are commonly prescribed to patients with metabolic
syndrome or those with multiple cardiovascular disease risk
factors when lifestyle changes fail to achieve LDL-C targets to
reduce the risk of coronary heart disease morbidity and
mortality. Indeed, statins are the most widely prescribed drug
in the United States and around the world. Many patients are
advised to continue daily exercise when statin therapy is
initiated. In recent years, there has been a growing movement
to begin prescribing statins to low-risk patients and to all
patients over the age of 50 years for the primary prevention of
cardiovascular disease (8),making the case for statins to be used
in primary prevention. This concept is gaining momentum as
inexpensive generic statins have become available.
Although reports from pharmaceutical trials indicate that
statins are generally well-tolerated, statins have been linked
to skeletal muscle cramping, pain, myalgia, and, in rare
cases, rhabdomyolysis (9). Statins are poorly tolerated among
elite athletes (10) and may increase susceptibility to muscle
damage during exercise (11,12). Although the mechanisms
are poorly understood, some statins (simva-, atorva-, ﬂuva-)
have been shown to reduce skeletal muscle mitochondrial
content and oxidative capacity in humans (13–16). In
rodents, atorvastatin lowers running capacity (17,18) and
impairs exercise-mediated mitochondrial adaptations in
skeletal muscle (18). Despite the potential public health
implications, studies examining the beneﬁts and risks of
combining statins and exercise in humans are limited.
This randomized, controlled trial was designed to
compare the effects of exercise training to those of simvas-
tatin in combination with exercise on changes in cardiore-
spiratory ﬁtness and skeletal muscle citrate synthase activity,
a marker of skeletal muscle mitochondrial content, in
previously sedentary, overweight, or obese patients with at
least 2 metabolic syndrome risk factors.Methods
Participants. Volunteers were recruited through advertise-
ments andword-of-mouth and underwent a thoroughmedical
screening to determine eligibility. Volunteers were eligible if
they were between 25 and 59 years of age, overweight, or obese
(body mass index [BMI]: 26 to 39 kilograms of body weightper height inmeters squared), sedentary (nomore than 30min
of structured physical activity per week during the previous 6
months),weight stable (change in bodyweight of nomore than
5% during the previous 3 months), and had at least 2 of the 5
metabolic syndrome risk factors as deﬁned by the National
Cholesterol Education Program’s Adult Treatment Panel III.
Exclusion criteria included smoking, the use of statins or other
medications or supplements that affect lipid proﬁles or body
weight (e.g., ﬁbric acids, bile acid sequestrants, nicotinic acids,
ﬁsh oil), changes in the use or dose of other medications or
supplements during the previous 3 months, diagnosis of
chronic diseases including cardiovascular disease, diabetes
mellitus, other metabolic diseases (e.g., thyroid), cancer,
human immunodeﬁciency virus or acquired immunodeﬁ-
ciency syndrome, positive graded exercise stress test, or
musculoskeletal or other problems that result in an inability to
walk on a treadmill. The study was approved by the Health
Sciences Institutional Review Board at the University of
Missouri. All volunteers provided written informed consent.
Study design. We used a block-randomized design to assign
eligible participants to a 12-week supervised aerobic exercise
training program or to the exercise program in combination
with daily simvastatin use. Group assignment was stratiﬁed
according to age, sex, and BMI.
The supervised exercise training program began with
30 min of treadmill walking or jogging at 60% to 75% of heart
rate reserve (equivalent to approximately 60% to 75% of peak
oxygen consumption [Vo2peak]) on 3 days during the ﬁrst
week and on 5 days during the second week, where 60% of
heart rate reserve ¼ [(peak heart rate during treadmill test –
resting heart rate)  0.60] þ resting heart rate. During the
remaining 12 weeks, participants completed 45 min of tread-
mill walking or jogging at 60% to 75% of heart rate reserve
5 days per week. Exercise intensity was monitored via Polar
heart rate monitors as previously described (19). Adherence
was calculated as the number of exercise sessions completed
divided by the number of sessions prescribed. Exercise sessions
were performed in a ﬁtness facility on the University of
Missouri campus under close supervision by study staff.
Participants assigned to the combination group partici-
pated in the exercise training program and were given 40 mg
simvastatin per day (20).
Assessments. Assessments were completed at baseline and
at the end of the 12-week intervention. Body weight, height,
and waist circumference were measured, and body compo-
sition was determined using a QDR-4500A dual X-ray
absorptiometry (Hologic, Shelby Township, Michigan).
Blood pressure was measured using a mercury sphygmo-
manometer following 10 min of seated rest.
Blood samples were collected after a 12-hr overnight fast.
Fasting glucose was determined using the glucose oxidase
method. Fasting insulin was measured by enzyme-linked
immunosorbant assays. Total cholesterol, high-density lipo-
protein cholesterol, LDL-C, and triglycerides were measured
by immunocalorimetric assays by a commercial labororatory.
LDL-C was calculated using the Friedewald equation (21).
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711On the same day, biopsies (50 to 100 mg) were obtained
from the vastus lateralis muscle using the modiﬁed
Bergstrom needle technique (22). Skeletal muscle samples
were immediately cleaned of visible connective and adipose
tissue and snap frozen in liquid nitrogen. Citrate synthase,
a marker of skeletal muscle mitochondrial content (23),
was measured by spectrophotometry (24). Quantiﬁcation of
mitochondrial oxidative phosphorylation proteins was
determined by immunoblotting (25) using the MitoProﬁle
Total OXPHOS antibody (Abcam, Cambridge, Massa-
chusetts) (26). Insufﬁcient tissue volume precluded the
analysis of a small subset of samples. Thus, baseline and
post-intervention skeletal muscle citrate synthase activity
and mitochondrial oxidative phosphorylation protein
content are presented on samples from 13 patients in the
simvastatin plus exercise group and 17 in the exercise group.
A 3-day dietary control period preceded the blood
collection and muscle biopsy visits. Participants were given
a food diary and instructed to follow habitual food intake
patterns while recording the type, timing, and amount of
food and beverage consumed for the 3 days preceding the
pre-intervention blood collection and muscle biopsy.
Participants were later given a copy of their food diary and
instructed to replicate the amount, timing, and type of food
and beverage consumed for 3 days prior to the post-
intervention blood collection and muscle biopsy.
Expired gases were analyzed by a metabolic cart
(TrueOne 2400, Parvo Medics, Salt Lake City, Utah)
during a ramped treadmill test (Bruce protocol) (19) to
determine cardiorespiratory ﬁtness (Vo2peak). Resting and
peak heart rate were determined by electrocardiography.
Vo2peak was obtained when participants reached volitional
exhaustion and met at least 3 of the following criteria:
1) respiratory exchange ratio 1.10; 2) peak heart rate
within 10 beats of age predicted maximum; 3) rating of
perceived exertion 18; or 4) plateau in oxygen consump-
tion despite increase in workload (19).Table 1 Subject Characteristics
Ex (n ¼ 18)
Pre P
Age, yrs 43.8  12.9
Sex 7 male; 11 female
Weight, kg 97.9  18.4 96.23
BMI, kg/m2 33.9  4.6 33.3
Body fat, % 39.3  6.3 38.5
Fat mass, kg 38.0  8.5 36.6
Lean body mass, kg 58.1  12.6 57.8
Fasting glucose, mmol/l 4.86  0.53 4.80
Triacylglycerol, mg/dl 142.2  91.1 127.9
Total cholesterol, mg/dl 190.7  50.7 193.3
LDL-C, mg/dl 122.7  37.1 125.6
HDL-C, mg/dl 44.2  9.6 47.11
Values are mean  SD. Subject characteristics before and after 12 weeks of
therapy. *p < 0.05 for between-group difference in change from baseline. yp <
BMI ¼ body mass index; Ex ¼ exercise; HDL-C ¼ high-density lipoprotein; LD
Ex ¼ exercise-plus-statin therapy.Statistical analysis. The main effects of time (baseline vs.
post-intervention), treatment (exercise alone vs. exercise plus
statin), and time-by-treatment interactions (between-group
differences in change from baseline) were tested using 2-way
repeated measures analysis of variance. Where signiﬁcant
main effects were found, post hoc tests were performed
with least signiﬁcant difference to identify speciﬁc pairwise
differences. All statistical analyses were performed with SPSS
(version 19.0, SPSS Inc., Armonk, New York). Statistical
signiﬁcance was set at p < 0.05. Data in ﬁgures are shown as
mean  SE; data in Table 1 are shown as mean  SD.Results
Study participants. Forty-one eligible volunteers were
randomized to the exercise-alone (n ¼ 21) or exercise-plus-
statin (n ¼ 20) groups. All participants were statin-naïve.
Three participants withdrew from the exercise group: 1 due
to time constraints; 1 because of a desire to lose weight; and
1 because of a foot injury occurring outside of the inter-
vention. One participant was released from the exercise-
plus-statin group due to complications unrelated to the
intervention. Thirty-seven participants (13men and 24women)
completed the study. Cardiorespiratory ﬁtness and blood
variables are available from 18 participants in the exercise-
only group and 19 participants from the exercise-plus-statin
group. Skeletal muscle citrate synthase activity data is avail-
able in a subset of participants (12 statin-plus-exercise
subjects and 17 exercise-only subjects).
At baseline, there were no differences between the groups
for any of the outcome variables measured (Table 1).
Adherence. There were no group differences in adherence
to the exercise program, with participants in the exercise-only
group completing 95 2% of prescribed exercise sessions and
participants in the statins-plus-exercise group completing
95  1% of prescribed sessions. Medication adherence was
not quantiﬁed but was monitored by asking participants if theySt þ Ex (n ¼ 19)
ost Pre Post
42.5  9.6
6 male; 13 female
 18.3*y 98.2  19.8 98.9  21.4
 4.6 33.9  4.6 34.2  5.1
 6.4y 40.3  6.5 39.7  6.3
 8.0y 39.7  11.6 39.4  11.9
 13.2 55.5  12.7 56.7  13.6*z
 0.57 4.95  0.35 5.04  0.45
 81.4 124.4  71.3 94.2  45.5
 54.7 203  51.0 144.6  25.8*x
 43.8 147.9  55.2 90.9  31.2*x
 13.2 45.8  12.1 45.6  12.5
supervised aerobic exercise training or combination exercise-plus-statin
0.05; zp < 0.01; and xp< 0.001 for within-group change from baseline.
L-C ¼ low-density lipoprotein cholesterol; Pre ¼ before; Post ¼ after; St þ
AB
Figure 1 Cardiorespiratory Fitness
(A) Peak oxygen consumption (Vo2peak) before (Pre) and after (Post) 12 weeks of
supervised aerobic exercise training (Ex) or combination exercise-plus-statin
therapy (StþEx). (B) Vo2peak presented as within-group change (D) from baseline.
Data are expressed as mean  SE. *p < 0.005 for within-group change from
baseline. xp < 0.005 for between-group difference in change from baseline.
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712had any problems taking the medication. In addition, choles-
terol was uniformly lowered in the statin group providing
evidence that mediation adherence was more than adequate.
Effects of intervention on anthropometric outcomes. At
12 weeks, body weight decreased signiﬁcantly in the exercise
group (p < 0.01 for change within group) but not the
exercise-plus-statin group (p < 0.01 for between-group
difference in change from baseline) (Table 1). Similarly,
there was a signiﬁcant decrease in fat mass in the exercise
group (p < 0.05). In the exercise-plus-statin group, the
decrease in fat mass approached signiﬁcance (p ¼ 0.056).
Lean body mass increased signiﬁcantly in the exercise-plus-
statin group only (p < 0.05 for with-in group change from
baseline; p < 0.05 for difference in between-group change
from baseline). BMI was not changed in either group.
Effects of intervention on lipid proﬁles. Lipid proﬁles are
shown in Table 1. Total cholesterol decreased by 29%
(p< 0.001 for within-group change frombaseline), andLDL-
C decreased by 38% (p < 0.001) in the exercise-plus-statin
group. There were no signiﬁcant changes in total cholesterol
or LDL-C in the exercise group (p< 0.001 for between-group
differences in change frombaseline).High-density lipoprotein
cholesterol did not change signiﬁcantly in either group.
Effects of intervention on cardiorespiratory ﬁtness. Sim-
vastatin signiﬁcantly attenuated increases in cardiorespira-
tory ﬁtness (Vo2peak, expressed as milliliters of oxygen
consumed per kilogram of body weight per minute), in
response to the exercise training program (p < 0.005 for
between-group difference in change from baseline) (Fig. 1A).
Cardiorespiratory ﬁtness, increased by 10% in response to
exercise training alone (p < 0.005 for change from baseline)
but did not increase signiﬁcantly in the group assigned to
combined exercise-plus-statin therapy (Fig. 1B).
Because total body mass and fat mass decreased signiﬁ-
cantly in the exercise group and lean mass increased in the
exercise-plus-statin group, we also compared changes in
cardiorespiratory ﬁtness expressed as absolute Vo2peak (total
liters of oxygen consumed per minute), Vo2peak relative to
lean body mass (milliliters of oxygen consumed per kilogram
of lean body mass per minute), treadmill time to exhaustion
(seconds), as well as peak workload (metabolic equivalents).
Regardless of how the data were expressed, cardiorespiratory
ﬁtness increased signiﬁcantly in response to exercise training
alone but not in response to exercise-plus-statin (p < 0.005
for between-group difference in change from baseline),
indicating that simvastatin signiﬁcantly attenuated exercise-
mediated increases in cardiorespiratory ﬁtness.
Effects of intervention on skeletal muscle citrate synthase
activity. Simvastatin prevented exercise-training-induced
increases in skeletal muscle citrate synthase activity, a marker
of mitochondrial content (p < 0.05 for between-group differ-
ence in change from baseline) (Fig. 2). Skeletal muscle citrate
synthase activity increased by 13% in the exercise-only group
(p < 0.05 for change from baseline) and decreased by 4.5% in
the exercise-plus-statin group (not signiﬁcant for change from
baseline) (Fig. 2). Similar patterns were observed in the proteincontent of skeletal muscle mitochondrial complexes I, II, III,
and IV (data not shown), providing further evidence that statins
minimized or negated responses to exercise training.
Discussion
In this trial, simvastatin abated improvements in cardiore-
spiratory ﬁtness and skeletal muscle citrate synthase activity,
a marker of mitochondrial content, following 12 weeks of
aerobic exercise training in overweight and obese volunteers at
risk for metabolic syndrome. The results have direct clinical
ramiﬁcations as patients at risk for metabolic syndrome are
commonly prescribed statins to lower blood lipids and at the
same time advised to exercise to improveﬁtness, both ofwhich
are independently proven to lower cardiovascular disease risk.
During exercise, skeletal muscle energy ﬂux and mito-
chondrial respiration are increased to provide adenosine
triphosphate for muscle contractions. Exercise also stimu-
lates transcriptional responses that, if repeated over time,
promote mitochondrial biogenesis (increase in number or
content) and increase mitochondrial oxidative capacity
(improved function). These adaptations, which lead to
greater capacity for skeletal muscle oxygen consumption, are
AB
Figure 2
Citrate Synthase Activity, a Marker of
Skeletal Muscle Mitochondrial Content
(A) Citrate synthase activity before and after 12 weeks of supervised aerobic
exercise training or combination exercise-plus-statin therapy. (B) Citrate synthase
activity presented as within-group change from baseline. Data are expressed as
mean  SE. *p < 0.05 for within-group change from baseline. xp < 0.05 for
between-group difference in change from baseline. Abbreviations as in Figure 1.
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713a key component of exercise-mediated improvements in
cardiorespiratory ﬁtness. Our ﬁndings suggest that simvas-
tatin may mitigate improvements in ﬁtness in response to
exercise training by impairing increases in skeletal muscle
mitochondrial content and function. In support of these
data, physiologic doses of simvastatin disrupt mitochondrial
respiration, increase oxidative stress, and activate mitochon-
drial apoptotic pathways in isolated skeletal muscle ﬁbers
(27). Similar observations have been reported in studies of
muscle ﬁbers taken from patients using statins (28), and high-
dose simvastatin (80 mg/day) has been shown to decrease
skeletal muscle mitochondrial content in the absence of
exercise (29,30). Statins have also been shown to reduce
skeletal muscle force production (31), running capacity
(17,18), and voluntary running volume (31) in rodents.
Collectively, these data indicate that statins may induce
mitochondrial oxidative stress, which activates pathways of
apoptosis or autophagy, mitigating increases in mitochondrial
content and oxidative capacity in response to exercise training.
It should be mentioned that a placebo was not given to
participants in the exercise-only group.Thus, participantswere
aware of their group assignment, introducing the possibility of
a “placebo effect.” However, we do not think a placebo effectwas the cause of our outcomes when our data are considered in
light of accumulating evidence that statins can cause undesir-
able effects on skeletal muscle mitochondrial function (13–
18,27–30,32). One of the primary strengths of this trial is
the robust agreement between changes in functional (cardio-
respiratory ﬁtness) and biochemical (skeletal muscle citrate
synthase) outcomes in response to the interventions. To our
knowledge, this is the ﬁrst randomized controlled clinical trial
directly comparing the effects of exercise training to exercise-
plus-statins on changes in both functional and biochemical
outcomes in previously statin-naïve patients.
Therapeutic options that minimize the adverse effects of
LDL-C–lowering therapies on adaptions to exercise training
are warranted. Emerging evidence indicates that some statins
(e.g., pravastatin) may be less prone to disturbing skeletal
muscle mitochondrial content or function than are others
(33). Alternatively, coenzyme Q10 supplementation or
commencing exercise training prior to initiating statin therapy
may lessen some of the untoward effects of statins (17,31,34).
However, these ﬁndings are not always consistent (29), and
many therapeutic alternatives are in the early stages of inves-
tigation, indicating that further research is needed in this area.
Statins are widely prescribed in combination with exercise
to lower risk of cardiovascular disease morbidity and
mortality. Every 1 mmol/l reduction in LDL-C is associated
with a 10% to 20% reduction in risk of cardiovascular events
(35,36) and all-cause mortality (36), whereas every 1 meta-
bolic equivalent (3.5 ml of oxygen per kilogram of body
weight per minute) increase in ﬁtness is associated with an
18% reduction in cardiovascular disease mortality (37) and
an 11% to 50% reduction in all-cause mortality (7,37,38). As
cardiorespiratory ﬁtness increases, the predictive value of
LDL-C on coronary heart disease mortality is signiﬁcantly
attenuated in men (39). In a large, prospective study of
dyslipidemic veterans, both ﬁtness and statin use were
independently associated with low mortality, with the lowest
risk of mortality observed in highly ﬁt patients taking statins
(40). Notably, patients in the highest quartile of ﬁtness had
a 60% to 70% reduction in all-cause mortality relative to
patients in the lowest quartile of ﬁtness, irrespective of statin
use, and the low-ﬁt patients taking statins had a higher
risk of mortality than did the highly ﬁt patients not taking
statins. Collectively, these data indicate that maintaining or
improving cardiorespiratory ﬁtness may mitigate some of the
negative health consequences of elevated LDL-C. However,
we are unaware of randomized, placebo-controlled trials
directly comparing the long-term cardioprotective effects of
exercise alone to statins plus exercise. Until such studies are
undertaken, the relative importance of improving ﬁtness and
lowering LDL-C in moderating risk of cardiovascular events
and death should be carefully weighed in the clinical setting.
Conclusions
Simvastatin attenuates increases in cardiorespiratoryﬁtness and
skeletal muscle mitochondrial content associated with exercise
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714training inpreviously sedentary, overweight, or obesepatients at
risk of metabolic syndrome. Given the strong independent
cardioprotective effects of increasing cardiorespiratoryﬁtness or
lowering LDL-C, the beneﬁts and risks of each should be
carefully considered when choosing treatment modalities.
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